New study checks safety of apremilast for kids with painful mouth sores and arthritis

NCT ID NCT05767047

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of the drug apremilast in children aged 2 and older with Behçet's disease (causing mouth ulcers) or aged 5 and older with juvenile psoriatic arthritis. About 48 kids who finished a previous study will take apremilast for up to 52 more weeks. Researchers will track side effects, growth, and development to make sure the drug is safe over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHÇET'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behcet disease juvenile idiopathic arthritis Oral Ulcer psoriasis-related juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BEHÇET'S DISEASE JUVENILE PSORIATIC ARTHRITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

General Hospital of Thessaloniki Ippokrateio
RECRUITING

Thessaloniki, 54642, Greece
Hacettepe Universitesi Tip Fakultesi Hastanesi
RECRUITING

Ankara, 06100, Turkey (Türkiye)
Hospital Universitari i Politecnic La Fe
RECRUITING

Valencia, Valencia, 46026, Spain
Hospital Universitario Ramon y Cajal
RECRUITING

Madrid, 28034, Spain
Istanbul Universitesi Cerrahpasa Tip Fakultesi
RECRUITING

Istanbul, 34098, Turkey (Türkiye)
Meir Medical Center
RECRUITING

Kfar Saba, 4428164, Israel
Umraniye Egitim ve Arastirma Hastanesi
RECRUITING

Istanbul, 34764, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.